The gene expression change of MDA-MB-231 treated with HDAC/G4 dual-targeting compound

The HDAC/G4 dual compound a6 was developed to improve G4 targeting efficiency and anticancer activity in triple-negative breast cancer cells. In order to explore the relationship between G4 functions and a6 treatment, we performed RNA-seq to analyze the proportion of G4-related differentially expressed genes and KEGG pathway enrichment. The RNA-Seq data of MDA-MB-231 cells treated without (Ctrl) or with single-targeting compound (SAHA or 1) or dual-targeting compound (a6)